• KOL
    • Type 1 Diabetes
    • Chantal Mathieu⁎
    • Chantal Mathieu⁎: Influence Statistics

      Chantal Mathieu⁎

      Chantal Mathieu⁎

      Show email address

      Clinical and Experimental Endocrinology, Katholieke Universiteit Leuven, Leuven, Belgium; Universitair Ziekenhuis Gasthuisberg Leuven, Leuven, Belgium. | Department of ...

      Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile

      Chantal Mathieu⁎:Expert Impact

      Concepts for whichChantal Mathieu⁎has direct influence:Type 1 diabetes,Type 1,1 diabetes,Nod mice,Type 2 diabetes,Diabetes mellitus,2 diabetes,Type 2.

      Chantal Mathieu⁎:KOL impact

      Concepts related to the work of other authors for whichfor which Chantal Mathieu⁎ has influence:Type 2 diabetes,Vitamin deficiency,Insulin resistance,Glycemic control,Gene expression,Sglt2 inhibitors,Cardiovascular disease.

      KOL Resume for Chantal Mathieu⁎

      Year
      2022

      Clinical and Experimental Endocrinology, Katholieke Universiteit Leuven, Leuven, Belgium; Universitair Ziekenhuis Gasthuisberg Leuven, Leuven, Belgium.

      Department of Endocrinology, KU Leuven, Leuven, Belgium

      2021

      Department of Chronic Diseases and Metabolism, Laboratory for Clinical and Experimental Endocrinology, KU Leuven, Leuven, Belgium.

      Clinical and Experimental Endocrinology, UZ Gasthuisberg, University of Leuven, Leuven, Belgium

      2020

      Endocrinology, UZ Gasthuisberg, Leuven, Belgium

      2019

      Clinical and Experimental Endocrinology, University Hospital Gasthuisberg, Leuven, Belgium

      Département d'Endocrinologie clinique et expérimentale, UZ Gasthuisberg, KU Leuven, Belgique.

      2018

      Clinical and Experimental Endocrinology, KU Leuven, Belgium. Electronic address:

      Department of Endocrinology, University Hospitals Leuven-Katholieke Universiteit Leuven, Leuven, Belgium.

      UZ Leuven, Leuven, Belgium

      2017

      Department of Clinical and Experimental Medicine, Clinical and Experimental Endocrinology, KU Leuven, 3000, Leuven, Belgium

      Toronto, Ontario

      Sign-in to see all concepts, it's free!
      Sample of concepts for which Chantal Mathieu⁎ is among the top experts in the world.
      Concept World rank
      cgm relevance #1
      depict studies #1
      fast‐acting insulin #1
      monocytic expression behavior #1
      il1ra pnf #1
      absence irf1 #1
      iaa classification #1
      interdisciplinary diabetes #1
      nod mice effects #1
      glucose intolerance women #1
      exenatide bid cohort #1
      viral transduction efficacy #1
      cd40 sensitization #1
      adatarget #1
      bb pfd #1
      vitamin supplementation rehabilitation #1
      real life vildagliptin #1
      adhesion factors women #1
      adjustable insulin #1
      gir aucgir0 #1
      islet immune infiltrates #1
      vnotes laparoscopy #1
      endocrine hormone imbalances #1
      htx primary htx #1
      conversion vnotes #1
      cxcl10 alphacells #1
      otelixizumab 27 #1
      obstetrical center #1
      commercial witloof #1
      cereulide beta cells #1
      mir146b5p irak3 #1
      residence major roads #1
      hba1c 77 #1
      vitamin deficient mice #1
      glibenclamide prevents diabetes #1
      prostate autoimmune animals #1
      therapy window #1
      95 aqip #1
      enriched immune regulation #1
      tir hypoglycemia #1
      subspecies carnosum #1
      majority european societies #1
      tx527 1α25oh2d3 #1
      effects tx527 #1
      obese subjects inflammation #1
      gestational diabetes europe #1
      understanding dendritic #1
      ifngamma interferon gamma #1
      inds fgf23 #1
      blood sampling procoagulant #1
      Sign-in to see all concepts, it's free!

      Prominent publications by Chantal Mathieu⁎

      KOL-Index: 20749

      BACKGROUND: Dapagliflozin is a sodium-glucose cotransporter-2 inhibitor approved for the treatment of type 2 diabetes. We aimed to assess the efficacy and safety of dapagliflozin as an add-on to adjustable insulin in patients with inadequately controlled type 1 diabetes.

      METHODS: DEPICT-1 was a double-blind, randomised, parallel-controlled, three-arm, phase 3, multicentre study done at 143 sites in 17 countries. Eligible patients were aged 18-75 years and had inadequately controlled type ...

      Known for Dapagliflozin Patients | 1 Diabetes | Inadequately Controlled | 24 Week | Efficacy Safety
      KOL-Index: 19991

      The EVI1 gene, located at chromosome band 3q26, is overexpressed in some myeloid leukemia patients with breakpoints either 5' of the gene in the t(3;3)(q21;q26) or 3' of the gene in the inv(3)(q21q26). EVI1 is also expressed as part of a fusion transcript with the transcription factor AML1 in the t(3;21)(q26;q22), associated with myeloid leukemia. In cells with t(3;21), additional fusion transcripts are AML1-MDS1 and AML1-MDS1-EVI1. MDS1 is located at 3q26 170-400 kb upstream (telomeric) ...

      Known for Myeloid Leukemia | Mds1 Evi1 | Normal Tissues | Intergenic Splicing | New Member
      KOL-Index: 18341

      Aims/hypothesisThis study aimed to determine the characteristics and pregnancy outcomes across different subtypes of gestational diabetes mellitus (GDM) based on insulin resistance.MethodsGDM subtypes were defined in 1813 pregnant women from a multicentre prospective cohort study, stratified according to insulin resistance, based on Matsuda index below the 50th percentile of women with normal glucose tolerance (NGT), during a 75 g OGTT at 24–28 weeks’ gestation. GDM was diagnosed in ...

      Known for Insulin Resistance | Pregnancy Outcomes | Women Gdm | Gestational Diabetes | Preterm Delivery
      KOL-Index: 18020

      Aims/hypothesisCytokines and chemokines are important mediators of immune responses due to their ability to recruit and activate leukocytes. Using microarray analysis we observed that rat beta cells exposed to IL-1β and IFN-γ have increased mRNA levels of chemokines and IL-15. The aim of this study was to characterize the expression of IP-10, MIP-3α, fractalkine and IL-15 in rat beta cells, human pancreatic islets, and in islets isolated from NOD mice, both during the pre-diabetic period ...

      Known for Nod Mice | Islet Cells | Ifnγ Expression | Rat Pancreatic | Il1β Ifn
      KOL-Index: 17728

      BACKGROUND: Glucagon-like peptide 1 receptor agonists differ in chemical structure, duration of action, and in their effects on clinical outcomes. The cardiovascular effects of once-weekly albiglutide in type 2 diabetes are unknown. We aimed to determine the safety and efficacy of albiglutide in preventing cardiovascular death, myocardial infarction, or stroke.

      METHODS: We did a double-blind, randomised, placebo-controlled trial in 610 sites across 28 countries. We randomly assigned ...

      Known for Type 2 Diabetes | Cardiovascular Disease | Patients Placebo | Harmony Outcomes | Myocardial Infarction
      KOL-Index: 16658

      AIM: Hypoglycaemia and the fear of hypoglycaemia are barriers to achieving normoglycaemia with insulin. Insulin degludec (IDeg) has an ultra-long and stable glucose-lowering effect, with low day-to-day variability. This pre-planned meta-analysis aimed to demonstrate the superiority of IDeg over insulin glargine (IGlar) in terms of fewer hypoglycaemic episodes at equivalent HbA1c in type 2 and type 1 diabetes mellitus (T2DM/T1DM).

      METHODS: Pooled patient-level data for self-reported ...

      Known for Ideg Iglar | Insulin Glargine | Type 1 | 3 Trials | Hypoglycaemia Risk
      KOL-Index: 16070

      AIMS: Canagliflozin is a sodium glucose co-transporter 2 inhibitor developed for the treatment of type 2 diabetes mellitus (T2DM). This randomised, double-blind, placebo-controlled, Phase 3 study evaluated the efficacy and safety of canagliflozin as an add-on to metformin plus sulphonylurea in patients with T2DM.

      METHODS: Patients (N = 469) received canagliflozin 100 or 300 mg or placebo once daily during a 26-week core period and a 26-week extension. Prespecified primary end-point was ...

      Known for Canagliflozin Placebo | Hba1c Week | Diabetes Mellitus | Type 2 | Efficacy Safety
      KOL-Index: 15829

      BACKGROUND: Our aim was to evaluate the difference in pregnancy outcomes and characteristics between insulin- and diet-treated women with gestational diabetes (GDM).

      METHODS: Retrospective analysis of the medical files from 2010-2013 of women with GDM diagnosed with the Carpenter & Coustan criteria attending two clinics, one in a university and another in a non-university hospital. Characteristics associated with insulin use were analyzed. Multivariable logistic regression was used to ...

      Known for Gestational Diabetes | Pregnancy Outcomes | Women Gdm | Treated Insulin | Hypoglycemic Agents
      KOL-Index: 15559

      OBJECTIVE: In 2016, nationwide reimbursement of intermittently scanned continuous glucose monitoring (isCGM) for people living with type 1 diabetes treated in specialist diabetes centers was introduced in Belgium. We undertook a 12-month prospective observational multicenter real-world study to investigate impact of isCGM on quality of life and glycemic control.

      RESEARCH DESIGN AND METHODS: Between July 2016 and July 2018, 1,913 adults with type 1 diabetes were consecutively recruited in ...

      Known for 1 Diabetes | Quality Life | Glucose Monitoring | Severe Hypoglycemia | Intermittently Scanned
      KOL-Index: 15102

      EVI1, located at chromosome band 3q26, encodes a 1051 amino acid zinc finger protein inappropriately expressed in the leukemic cells of 2–5% of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) patients. The activation of EVI1 often follows a chromosomal rearrangement involving band 3q26, and the two most frequent rearrangements are the t(3;3)(q21;q26) and the inv(3)(q21q26). EVI1 exists also as a longer protein that includes 188 additional amino acids at the N-terminus, ...

      Known for Mds1 Evi1 | Leukemia Myeloid | Dna Binding | Transcription Factors | Myelodysplastic Syndrome
      KOL-Index: 15084

      OBJECTIVE: This multicenter, treat-to-target, phase 3 trial evaluated the efficacy and safety of fast-acting insulin aspart (faster aspart) versus conventional insulin aspart (IAsp) in adults with type 1 diabetes.

      RESEARCH DESIGN AND METHODS: The primary end point was change from baseline in HbA1c after 26 weeks. After an 8-week run-in, subjects were randomized (1:1:1) to double-blind mealtime faster aspart (n = 381), IAsp (n = 380), or open-label postmeal faster aspart (n = 382)-each ...

      Known for Insulin Aspart | Type 1 Diabetes | Glycemic Control | Iasp Mealtime | Meal Test
      KOL-Index: 14943

      OBJECTIVE: This study investigated the efficacy and safety of insulin degludec (IDeg) once daily (OD), varying injection timing day to day in subjects with type 1 diabetes.

      RESEARCH DESIGN AND METHODS: This 26-week, open-label, treat-to-target, noninferiority trial compared IDeg forced flexible (Forced-Flex) OD (given in a fixed schedule with a minimum 8 and maximum 40 hours between doses) with IDeg or insulin glargine (IGlar) given at the same time daily OD. In the 26-week extension, ...

      Known for Insulin Glargine | Ideg Iglar | 1 Diabetes | Flexible Dosing Regimen | Time Day
      KOL-Index: 14921

      Apoptosis of pancreatic beta cells is a feature of type 2 diabetes and its prevention may have therapeutic benefit. High glucose concentrations induce apoptosis of islet cells, and this requires the proapoptotic Bcl-2 homology domain 3 (BH3)-only proteins Bim and Puma. We studied the stress pathways induced by glucotoxicity in beta cells that result in apoptosis. High concentrations of glucose or ribose increased expression of the transcription factor CHOP (C/EBP homologous protein) but ...

      Known for Oxidative Stress | Pancreatic Islets | Endoplasmic Reticulum | Type 2 Diabetes | Glucose Concentrations
      KOL-Index: 14857

      BACKGROUND & AIMS: The prevalence of nonalcoholic fatty liver disease (NAFLD) has increased with the obesity pandemic. We analyzed the transcriptional profiles of subcutaneous adipose tissue (SAT) and visceral adipose tissue (VAT), and phenotypes and functional characteristics of adipocyte tissue macrophages (ATMs), in obese patients undergoing bariatric surgery.

      METHODS: We collected anthropometric data; plasma samples; and SAT, VAT, and liver tissues from 113 obese patients undergoing ...

      Known for Patients Nash | Histologic Severity | Liver Disease | Tissue Inflammation | Nafld Vat

      Key People For Type 1 Diabetes

      Top KOLs in the world
      #1
      John M Lachin
      type 1 diabetes cardiovascular disease complications trial
      #2
      David Matthew Nathan
      type 2 diabetes insulin resistance cardiovascular disease
      #3
      William V Tamborlane
      type 1 diabetes young children growth hormone
      #4
      Patricia A Cleary
      type 1 diabetes optic neuritis intensive therapy
      #5
      George S Eisenbarth
      type 1 diabetes nod mice celiac disease
      #6
      Marian J Rewers
      type 1 diabetes islet autoimmunity celiac disease

      Clinical and Experimental Endocrinology, Katholieke Universiteit Leuven, Leuven, Belgium; Universitair Ziekenhuis Gasthuisberg Leuven, Leuven, Belgium. | Department of Endocrinology, UZ Gasthuisberg, KU Leuven, Leuven, Belgium. | Clinical and Experim

    Download on the App StoreGet it on Google Play

    Copyright © 2023 Key Opinion Leaders, LLC.